Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill replace injections to fight advanced prostate cancer?

NCT ID NCT06837896

Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This Phase 3 trial tests an oral drug called QLG1080 in men with hormone-sensitive advanced prostate cancer. The goal is to see if the drug can safely lower testosterone to castration levels, which helps slow cancer growth. Participants must be eligible for endocrine therapy and able to continue androgen deprivation for at least six months. The study measures how many men maintain castration-level testosterone over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
QLG1080, an oral drug being tested to lower testosterone to castration levels in men with advanced prostate cancer
What this could lead to
If QLG1080 works, it could offer a new oral option to suppress testosterone and help control advanced prostate cancer without injections.
What could go wrong
This is an early-stage test in a small group of 111 men. The drug may not maintain castration levels in all patients, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

111 people

The number who actually took part.

Started

Mar 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Histological or cytological diagnosis of prostate cancer;； * Advanced prostate cancer patients eligible for endocrine therapy, able to receive continuous androgen deprivation therapy for at least 6 months. * Serum testosterone ≥150 ng/dL (5.2nmol/L) at screening visit; * The Eastern Cooperative Oncology Group (ECOG) score is 0 to 1. Exclusion Criteria: * Diagnosed or suspected of hormone-resistant prostate cancer; * For prostate cancer patients who have had or are undergoing endocrine therapy * Patients who have previously undergone pituitectomy or adrenalectomy or have pituitary disease or adrenal dysfunction; * Those who have had any prostate surgery within 4 weeks prior to initial dosing or prostate surgery or other major surgical treatment during the planned trial period (except urinary tract obstruction relief); * The imaging results of screening visits clearly showed the presence of brain metastases;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • No. 8888 Lvyou Road

    Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.